GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $1.34 | $1.26 | $0.70 |
| Estimado | $1.33 | $1.25 | $1.16 | $0.62 |
| Sorpresa | — | +7.2% | +8.6% | +12.9% |
| Métrica | GSK | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 72.4% | 57.4% | +15.0% |
| Operating Margin | 24.3% | -34.4% | +58.7% |
| Net Margin | 17.5% | -32.5% | +50.0% |
| FCF Margin | 19.6% | -12.6% | +32.2% |
| ROE | 34.9% | -39.2% | +74.1% |
| ROA | 9.3% | -30.9% | +40.3% |
| Current Ratio | 0.82 | 2.73 | -1.91 |
| Debt / Equity | 0.90 | 0.28 | +0.62 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 9.4% | — |
| ✓Flujo de caja operativo positivo | £7.7B | £6.6B |
| ✓Rentabilidad sobre activos al alza | 9.4% | 4.3% |
| ✓Caja operativa/activos supera al ROA | 12.7% | ROA 9.4% |
| ✓Menos deuda a largo plazo | 24.1% | 24.6% |
| ✓Mejor liquidez (ratio corriente) | 0.82 | 0.78 |
| ✓Sin aumentar el nº de acciones | 4,117M | 4,142M |
| ✓Margen bruto al alza | 72.4% | 71.2% |
| ✓Rotación de activos al alza | 0.53 | 0.53 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 19.6% |
| ✓ROCE > 10 % | 20.0% |
| ✗Ventas > 5 %/año (3 años) | 3.7% |
| ✓Deuda neta/EBITDA < 3x | 1.1x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 27.2% |
GSK plc cotiza a 49.51 USD y tiene una capitalización bursátil de $99.2B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud